Eupraxia Pharmaceuticals Inc Quick Ratio (EPRX) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Eupraxia Pharmaceuticals Inc   (NASDAQ: EPRX)

Eupraxia Pharmaceuticals Inc 's Quick Ratio

EPRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 14.51 above Eupraxia Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Quick Ratio than Eupraxia Pharmaceuticals Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 183 to 196.

Explain Quick Ratio?
How much Cash & cash equivalents EPRX´s has?
What are EPRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EPRX Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 22.66 % 83.06 % 83.06 % 83.06 % -70.13 %
Y / Y Cash & cash equivalent Change 143.38 % 143.38 % 143.38 % 143.38 % 71.14 %
Quick Ratio MRQ 14.51 14.52 14.52 14.52 7.31
EPRX's Total Ranking # 196 # 183 # # #
Seq. Current Liabilities Change 0.03 % 0 % 0 % 22.63 % 49.28 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 143.38 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 46
Healthcare Sector # 68
Overall Market # 196


Quick Ratio Statistics
High Average Low
14.52 12.72 10.92
(Dec 31 2025)   (Dec 31 2024)




Financial Statements
Eupraxia Pharmaceuticals Inc 's Current Liabilities $ 6 Millions Visit EPRX's Balance sheet
Eupraxia Pharmaceuticals Inc 's Cash & cash equivalent $ 81 Millions Visit EPRX's Balance sheet
Source of EPRX's Sales Visit EPRX's Sales by Geography


Cumulative Eupraxia Pharmaceuticals Inc 's Quick Ratio

EPRX's Quick Ratio for the trailling 12 Months

EPRX Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 62.99 % -12.67 % -24.58 % -25.65 % -27.06 %
Y / Y Cash & cash equivalent TTM Growth 143.38 % 131.61 % 135.88 % 184.27 % 338.83 %
Quick Ratio TTM 14.52 12.98 12.19 11.15 9.72
Total Ranking TTM # 3820 # 0 # # #
Seq. Current Liabilities TTM Growth 4.84 % 13.5 % 15.6 % 18.49 % -43.83 %
Seq. Cash & cash equivalent TTM Growth 17.27 % 20.88 % 26.39 % 35.85 % 11.6 %

Quick ratio ranking by company, industry and sector >> Back to EPRX Financial Strength Comparisons >> Go to Compare EPRX Quick Ratio to its Competitors

On the trailing twelve months basis EPRX Cash & cash equivalent more than doubled by 143.38 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Eupraxia Pharmaceuticals Inc 's Quick Ratio to 14.52, above EPRX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 470 other companies have achieved higher Quick Ratio than Eupraxia Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 3820.

Explain Quick Ratio?
How much Cash & cash equivalents EPRX´s has?
What are EPRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 471
Healthcare Sector # 928
Within the Market # 3820


trailing twelve months Quick Ratio Statistics
High Average Low
14.31 12.49 10.67
(Dec 31 2025)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Janux Therapeutics Inc   38.67 $ 966.567  Millions$ 24.997  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Curanex Pharmaceuticals Inc  36.30 $ 4.973  Millions$ 0.137  Millions
Prothena Corporation Public Limited Company  36.01 $ 307.531  Millions$ 8.539  Millions
Minerva Neurosciences Inc   35.93 $ 82.302  Millions$ 2.290  Millions
Ligand Pharmaceuticals Incorporated  33.03 $ 1,236.811  Millions$ 37.447  Millions
Roivant Sciences Ltd   32.71 $ 4,886.891  Millions$ 149.411  Millions
Disc Medicine Inc   32.19 $ 791.152  Millions$ 24.579  Millions
Fulcrum Therapeutics Inc   27.00 $ 352.306  Millions$ 13.048  Millions
Contineum Therapeutics Inc   26.98 $ 262.896  Millions$ 9.744  Millions
Rapport Therapeutics Inc   25.75 $ 490.539  Millions$ 19.049  Millions
Upstream Bio Inc   25.39 $ 341.509  Millions$ 13.452  Millions
Mbx Biosciences Inc   24.12 $ 373.705  Millions$ 15.495  Millions
Structure Therapeutics Inc   22.85 $ 1,446.197  Millions$ 63.285  Millions
Monopar Therapeutics Inc   22.61 $ 61.834  Millions$ 2.735  Millions
Kairos Pharma Ltd   22.57 $ 4.491  Millions$ 0.199  Millions
Sagimet Biosciences inc   22.52 $ 113.124  Millions$ 5.023  Millions
Dyne Therapeutics Inc   21.94 $ 1,110.562  Millions$ 50.625  Millions
Arca Biopharma Inc  21.92 $ 337.044  Millions$ 15.374  Millions
Aprea Therapeutics Inc   20.46 $ 14.599  Millions$ 0.714  Millions
Spyre Therapeutics Inc   20.40 $ 1,197.428  Millions$ 58.685  Millions
Jade Biosciences Inc   20.33 $ 336.158  Millions$ 16.539  Millions
Siga Technologies Inc  19.99 $ 154.966  Millions$ 7.753  Millions
Trevi Therapeutics Inc   19.94 $ 188.260  Millions$ 9.442  Millions
Edgewise Therapeutics inc   19.37 $ 530.109  Millions$ 27.370  Millions
Maplight Therapeutics Inc   18.80 $ 305.103  Millions$ 16.229  Millions
Kezar Life Sciences Inc   16.92 $ 71.878  Millions$ 4.248  Millions
Stoke Therapeutics Inc   16.90 $ 284.670  Millions$ 16.840  Millions
Design Therapeutics Inc   16.84 $ 219.845  Millions$ 13.055  Millions
Neurogene Inc   16.39 $ 269.013  Millions$ 16.411  Millions

Date modified: 2026-07-07T10:40:17+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.